anti-PCSK9 antibody product blog
Tags: Antibody; PCSK9; Polyclonal Antibody; anti-PCSK9 antibody;
The PCSK9 pcsk9 (Catalog #MBS9214927) is an Antibody produced from Rabbit and is intended for research purposes only. The product is available for immediate purchase. The PCSK9 Antibody (C-term) reacts with Human and may cross-react with other species as described in the data sheet. MyBioSource\'s PCSK9 can be used in a range of immunoassay formats including, but not limited to, Western Blot (WB), ELISA (EIA).WB~~1:1000. Researchers should empirically determine the suitability of the PCSK9 pcsk9 for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
The PCSK9 pcsk9 product has the following accession number(s) (GI #31317307) (NCBI Accession #NP_777596.2) (Uniprot Accession #Q8NBP7). Researchers may be interested in using Bioinformatics databases such as those available at The National Center for Biotechnology Information (NCBI) website for more information about accession numbers and the proteins they represent. Even researchers unfamiliar with bioinformatics databases will find the NCBI databases to be quite user friendly and useful.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
Please refer to the product datasheet for known applications of a given antibody. We\'ve tested the PCSK9 Antibody (C-term) with the following immunoassay(s):
Western Blot (WB) (Western blot analysis of lysate from SK-N-MC cell line, using PCSK9 Antibody (C-term). MBS9214927 was diluted at 1:1000. A goat anti-rabbit IgG H&L(HRP) at 1:10000 dilution was used as the secondary antibody. Lysate at 20ug.)
Crucial player in the regulation of plasma cholesterol homeostasis. Binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation in intracellular acidic compartments. Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. Can induce ubiquitination of LDLR leading to its subsequent degradation. Inhibits intracellular degradation of APOB via the autophagosome/lysosome pathway in a LDLR-independent manner. Involved in the disposal of non-acetylated intermediates of BACE1 in the early secretory pathway. Inhibits epithelial Na(+) channel (ENaC)-mediated Na(+) absorption by reducing ENaC surface expression primarily by increasing its proteasomal degradation. Regulates neuronal apoptosis via modulation of LRP8/APOER2 levels and related anti-apoptotic signaling pathways.
Antigen Source: HUMAN. In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing PCSK9 are readily searchable from our website. Different antibodies against the same target such as PCSK9 may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results.